Korea Investment CORP Sells 12,150 Shares of Becton, Dickinson and Company $BDX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Korea Investment CORP lessened its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 198,344 shares of the medical instruments supplier's stock after selling 12,150 shares during the quarter. Korea Investment CORP owned approximately 0.07% of Becton, Dickinson and Company worth $45,433,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Aptus Capital Advisors LLC lifted its holdings in Becton, Dickinson and Company by 6.8% in the first quarter. Aptus Capital Advisors LLC now owns 14,651 shares of the medical instruments supplier's stock valued at $3,356,000 after buying an additional 927 shares during the period. Aviso Financial Inc. lifted its holdings in Becton, Dickinson and Company by 7.7% in the first quarter. Aviso Financial Inc. now owns 21,558 shares of the medical instruments supplier's stock valued at $4,938,000 after buying an additional 1,538 shares during the period. Northern Trust Corp boosted its stake in Becton, Dickinson and Company by 3.2% during the 1st quarter. Northern Trust Corp now owns 2,811,239 shares of the medical instruments supplier's stock worth $643,942,000 after acquiring an additional 86,885 shares during the last quarter. Foyston Gordon & Payne Inc boosted its stake in Becton, Dickinson and Company by 15.1% during the 1st quarter. Foyston Gordon & Payne Inc now owns 54,082 shares of the medical instruments supplier's stock worth $12,388,000 after acquiring an additional 7,075 shares during the last quarter. Finally, HFR Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 2.0% during the 1st quarter. HFR Wealth Management LLC now owns 33,276 shares of the medical instruments supplier's stock worth $7,622,000 after acquiring an additional 652 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 1.5%

Shares of NYSE BDX traded up $2.8730 during midday trading on Friday, reaching $199.5030. The company's stock had a trading volume of 1,619,788 shares, compared to its average volume of 2,720,196. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock has a market capitalization of $57.18 billion, a price-to-earnings ratio of 35.88, a PEG ratio of 1.49 and a beta of 0.20. The stock has a 50 day simple moving average of $180.65 and a 200-day simple moving average of $195.26.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the company earned $3.50 earnings per share. The firm's revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the sale, the director owned 23,143 shares in the company, valued at $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,214 shares of company stock worth $579,206 over the last ninety days. Insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BDX shares. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Stifel Nicolaus reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.